High-risk HPV L1 capsid protein as a marker of cervical intraepithelial neoplasia in high-risk HPV-positive women with minor cytological abnormalities

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 695-700

  Norman, Ingrid ^a   Hjerpe, Anders ^a   Andersson, Sonia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ASCUS; CIN; HPV; HPV L1 capsid protein; LSIL

Indexed keywords

CAPSID PROTEIN; L1 CAPSID PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ARTICLE; CANCER GRADING; CANCER SCREENING; CARCINOGENESIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FEMALE GENITAL TRACT CYTOLOGY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWEDEN; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CAPSID PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84879638725     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2538     Document Type: Article

References (24)

1. Bergstrom R, Sparen P and Adami HO: Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 81: 159-166, 1999. (Pubitemid 29415507)
2. Gunnell AS, Ylitalo N, Sandin S, Spärén P, Adami HO and Ripatti S: A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev 16: 2641-2648, 2007. (Pubitemid 351196320)
3. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P and Meijer CJ: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354: 20-25, 1999. (Pubitemid 29304297)
4. Muñoz N: Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19: 1-5, 2000.
5. Clifford GM, Smith JS, Aguado T and Franceschi S: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89: 101-105, 2003. (Pubitemid 36897943)
6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
7. Bosch FX and Muñoz N: The viral etiology of cervical cancer. Virus Res 89: 183-190, 2002.
8. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
9. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ and Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003.
10. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E and Wadell G: Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 171: 1026-1030, 1995.
11. Benton C, Shahidullah H and Hunter JAA: Human papillomavirus in the immunosuppressed. Papillomavirus Rep 3: 23-26, 1992.
12. Stanley M: Immune responses to human papillomavirus. Vaccine 24 (Suppl 1): S16-S22, 2006.
13. Song SH, Lee JK, Lee NW, Saw HS, Kang JS and Lee KW: Interferon-γ (IFN-γ): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecol Oncol 108: 543-548, 2008.
14. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, Taylor-Robinson D and Stanley MA: Immunological events in regressing genital warts. Am J Clin Pathol 102: 768-774, 1994.
15. Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R and Abadi M: Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 11: 483-488, 2002. (Pubitemid 34517944)
16. Griesser H, Sander H, Hilfrich R, Moser B and Schenck U: Correlation of immunochemical detection of HPV L1 capsid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia. Anal Quant Cytol Histol 26: 241-245, 2004. (Pubitemid 39458640)
17. Hilfrich R and Hariri J: Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol 30: 78-82, 2008. (Pubitemid 351501867)
18. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N; Forum Group Members; Bethesda 2001 Workshop: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119, 2002. (Pubitemid 34437346)
19. Richart RM: Cervical intraepithelial neoplasia. Pathol Annu 8: 301-328, 1973.
20. Brismar S, Johansson B, Borjesson M, Arbyn M and Andersson S: Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol 201: 17.e1-17.e8, 2009.
21. Melsheimer P, Kaul S, Dobeck S and Bastert G: Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 47: 124-128, 2003. (Pubitemid 36367917)
22. Griesser H, Sander H, Walczak C and Hilfrich RA: HPV vaccine protein L1 predicts disease outcome of high-risk HPV+ early squamous dysplastic lesions. Am J Clin Pathol 132: 840-845, 2009.
23. Luostarinen T, af Geijersstam V, Bjorge T, Eklund C, Hakama M, Hakulinen T, Jellum E, Koskela P, Paavonen J, Pukkala E, Schiller JT, Thoresen S, Youngman LD, Dillner J and Lehtinen M: No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 80: 818-822, 1999.
24. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P and Iftner T: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119: 1095-1101, 2006. (Pubitemid 44116919)